Yesterday (July 14), the official website of the Jiangsu Provincial Medical Insurance Bureau issued the "Jiangsu Provincial Department of Human Resources and Social Security Notice on the Publication of the Second Batch of Digestible Lists of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs List".

The document shows that the provincial medical insurance agencies must promptly maintain the information of the Jiangsu Provincial Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog Database, and transfer all the varieties under the generic name of the second batch of digestive drugs involved. At the same time, all drugs that were maintained under the generic name of the drug that did not comply with the current generic name rules were simultaneously transferred out. At the same time, Jiangsu Province announced that starting from January 1, 2022, the costs of all imported medicines will no longer be included in the payment scope of Jiangsu Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Fund. On November 3, 2020, Jiangsu Province released the first batch of digestive drugs, clarifying that from November 1, 2020, the first batch of 111 digestive drugs will be transferred out of the Jiangsu Provincial Medical Insurance Catalog, and the first batch of digestive drugs will be released from January 1, 2021. The expenses incurred are no longer included in the payment scope of Jiangsu Medical Insurance Fund. It is worth noting that more than 20 places such as Gansu, Jilin, Tianjin, Hebei, Anhui, Tibet, Beijing, Chongqing, Jiangsu, Qinghai, Sichuan, Henan, Ningxia, Xinjiang, Guangxi, Zhejiang, Shaanxi, Yunnan, Hunan and other places have been implemented. Supplement the catalog recall policy.

Pharmaceutical enterprise innovation is the key

Whether it is the 2021 new version of the National Medical Insurance Catalogue released at the end of June or the supplementary medicines accelerated by the provinces, it can be seen that although some medicines are in the medical insurance catalogue, it does not mean that they are worry-free. On August 20, 2019, the National Medical Insurance Administration issued the "Notice of the Ministry of Human Resources and Social Security of the National Medical Insurance Administration on Printing and Distributing the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog", clarifying that the original provincial drug catalog should be adjusted according to regulations. The Class B drugs should be gradually digested within 3 years. The proportions of varieties that were cleaned in three years were 40%, 40%, and 20%. Among them, the national key monitoring drugs were first brought out of the catalog. In the context of the reform of the medical system of "vacating the cage and changing the bird", some drugs with unclear clinical efficacy will be completely withdrawn from the list. From the perspective of the digestion of supplementary drugs in the medical insurance catalogs of various provinces, among the drugs currently being digested, large varieties of injections and proprietary Chinese medicines occupy a lot of space. Earlier, the National Medical Insurance Bureau mentioned in the public consultation of the whole society that the National Medical Insurance Catalogue will be adjusted in the future, in principle, it will be adjusted once a year. Cyberlan’s special author, Ma Wanqi, told Cyberlan today that making the national catalog a game of chess, dynamic adjustments and authoritative, is conducive to strengthening strategic purchases and large-scale purchases; it also makes medical insurance fund payments more effective and efficient, and medical insurance supports. The development of the pharmaceutical industry has a more strategic height. Under the background of the dynamic adjustment of the national medical insurance catalogue and the gradual digestion of drugs in the local medical insurance catalogue, the industry generally believes that in the future, pharmaceutical companies need to develop more innovative drugs in order to better occupy the market share.

Medicine representatives may need to transform

With the gradual digestion of a large number of provincial supplementary medicines, some medicines lose the market, and sales may see a cliff-like decline. According to previous statistics from the "Fengyun Medicine Talk" public account, the number of supplementary products for provincial medical insurance in the country exceeded 10,000 grades, and it is preliminary estimated that the cumulative amount of medical insurance used by the products is at least 100 billion. From these data, it can be seen that the market size is shrinking significantly. After the local medical insurance supplements are digested, the drug use pattern will change. For small and micro enterprises, they may face the situation of being acquired or sold. For medical representatives, it will also It will be a big challenge. For example, in 2019, Shutaishen's main product, Sutosan (mouse nerve growth factor for injection), withdrew from the medical insurance catalog. The net profit in the third-quarter performance report fell by 65.42%, and the gross profit margin fell back to 80%. In 2019, Harbin Pharmaceutical's high-margin product, Alprostadil Injection, was withdrawn from the National Medical Insurance Catalog. The sales revenue of this type of product of Harbin Pharmaceutical Co., Ltd. in 2018 was 179.41 million yuan, and the gross profit rate was as high as 77.26%. According to the report, the continued decline in net profit shows the great impact. When the drugs of some companies are transferred out of the medical insurance catalog, the relevant sales teams will inevitably be affected. Transferring or going to the grassroots to make new products, personnel optimization and adjustments are all realistic situations that will be faced. Under this circumstance, the above-mentioned people further analyzed and pointed out that for pharmaceutical companies, the company must organize from the inside to the outside, and set aside a "backward" internally to build a slide in order to make a smooth landing. Externally, it depends on the market, policies, and cooperation. At the same time, it is the key to do your own products carefully. He also said, “For medical representatives, in the context of deepening medical reform and building a great health, the business scope of medical representatives has typically narrowed, but they have always been well aware of the circulation of medicines, and they are the most able to squeeze the market’s rigid demand potential. Space. Under such circumstances, it is necessary for them to make academic promotion bigger and stronger, and make special and effective results. Combining with the needs of clinical development, help hospital doctors enhance the value of technical services. Properly look forward, stand in the perspective of hospital doctors, and face external competition. "

Appendix: